Overview

A Study of Postoperative Adjuvant Chemotherapy for Upper Urinary Urothelial Carcinoma With Lymphovascular Invasion

Status:
Not yet recruiting
Trial end date:
2023-06-01
Target enrollment:
0
Participant gender:
All
Summary
This project is to explore the effect of adjuvant chemotherapy on total tumor survival time, progression-free survival time, and recurrence-free survival time in patients with pTanyN0M0 upper urinary urothelial carcinoma with lymphatic vascular invasion (LVI) through a prospective case-control study.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Qinghua Xia,Prof
Treatments:
Cisplatin
Gemcitabine
Criteria
Inclusion Criteria:

1. Aged 20-85 years;

2. ECOG score 0-1 points;

3. Patients with UTUC, undergoing radical nephrectomy, pathological staging For
pTanyN0M0;

4. Patients voluntarily signed informed consent.

Exclusion Criteria:

1. Obvious cardiopulmonary dysfunction, serious diabetes and other chronic diseases;

2. Obvious chemotherapy contraindications;

3. Patients have a history of other organ malignancies;

4. Combined with tumors of other sites.